Page 21 - ஸ்பெயின் ஒன்றுபட்டது கிஂக்டம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article EXTON, Pa., Jan. 20, 2021 /PRNewswire/ Two 2020 European Medical Agency (EMA) approvals, Takeda s Entyvio SC and Celltrion Healthcare s infliximab biosimilar, Remsima SC, have captured notable shares among EU5 IBD patients, according to Spherix s recent report, RealTime Dynamix™: Inflammatory Bowel Disease (EU). The report sampled 246 EU5 gastroenterologists in November and December of 2020. While both new, subcutaneous market entrants have mostly gained prescribing momentum by cannibalizing their corresponding IV formulations, AbbVie s Humira stands out with its continual decline in EU5 IBD utilization.   Entyvio SC has managed to capture a sizeable portion of both the EU5 ulcerative colitis (UC) and Crohn s disease (CD) markets. This uptake is supported by the established familiarity that gastroenterologists have with Entyvio s IV formulation. Not surprisingly, Takeda is experiencing some cannibalization of Entyvio IV with the introdu

Abbvie humiraKristen hennJanssen stelaraEuropean medical agencyBusiness developmentMedical agencyCelltrion healthcareRealtime dynamixInflammatory bowel diseaseEuropean gastroenterology virtual weekRealworld dynamixSmall molecule switchingTime dynamixSpain united kingdomGlobal insightsSpherix global insights